After a rough year for Bayer and Johnson & Johnson's anticoagulant Xarelto, the companies hoped the competition would take it easy in 2019. Pfizer and Bristol-Myers Squibb's Eliquis had other plans.
(Reuters) - Bayer AG and Johnson & Johnson have agreed to settle more than 25,000 U.S. lawsuits alleging that their blockbuster blood thinner Xarelto caused unstoppable and in some cases fatal ...
FRANKFURT (Reuters) - Bayer and Johnson & Johnson's campaign to widen the patient group for their heart drug Xarelto hit a snag when two smaller studies failed to show a statistically reliant benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback